Lisa Walter
Stock Analyst at RBC Capital
(1.78)
# 807
Out of 5,182 analysts
23
Total ratings
33.33%
Success rate
-3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $128 → $142 | $101.29 | +40.19% | 1 | May 7, 2026 | |
| EYPT EyePoint | Maintains: Outperform | $39 → $37 | $13.40 | +176.12% | 3 | May 7, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $30 → $34 | $17.11 | +98.71% | 5 | May 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $136 → $137 | $95.27 | +43.80% | 3 | May 6, 2026 | |
| OCUL Ocular Therapeutix | Reiterates: Outperform | $30 | $9.60 | +212.66% | 1 | May 6, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $16 → $24 | $9.69 | +147.68% | 2 | Apr 17, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $32 → $35 | $9.99 | +250.35% | 3 | Mar 19, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $587 → $643 | $575.70 | +11.69% | 3 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $22 → $21 | $41.01 | -48.79% | 2 | Feb 25, 2026 |
Mirum Pharmaceuticals
May 7, 2026
Maintains: Outperform
Price Target: $128 → $142
Current: $101.29
Upside: +40.19%
EyePoint
May 7, 2026
Maintains: Outperform
Price Target: $39 → $37
Current: $13.40
Upside: +176.12%
Viridian Therapeutics
May 6, 2026
Maintains: Outperform
Price Target: $30 → $34
Current: $17.11
Upside: +98.71%
Rhythm Pharmaceuticals
May 6, 2026
Maintains: Outperform
Price Target: $136 → $137
Current: $95.27
Upside: +43.80%
Ocular Therapeutix
May 6, 2026
Reiterates: Outperform
Price Target: $30
Current: $9.60
Upside: +212.66%
MeiraGTx Holdings
Apr 17, 2026
Maintains: Outperform
Price Target: $16 → $24
Current: $9.69
Upside: +147.68%
4D Molecular Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $32 → $35
Current: $9.99
Upside: +250.35%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $587 → $643
Current: $575.70
Upside: +11.69%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $21
Current: $41.01
Upside: -48.79%